PLUR

Insider Trades

Name	Value	Action	Price	Last Price
Manieu Alexandre WeinsteinDirector, 10 Percent Owner: $2M523.4k shares BuyApr 28, 2025 $4.61 $1.86
Manieu Alexandre WeinsteinDirector, 10 Percent Owner: $2M452.7k shares BuyApr 28, 2025 $4.61 $1.86

News

newsfilecorp.comPlurilock Announces Results of Annual General Meetingnewsfilecorp.comJun 16

globenewswire.comPluri Advances Toward U.S. Commercial Launch Through Its Subsidiary Cellav, Following Completion of Regenerative Aesthetic Products Listingglobenewswire.comJun 2

Trade PLUR

About Pluri Inc.

Pluri Inc., a biotechnology company established in 2001 and headquartered in Haifa, Israel, specializes in developing innovative placenta-derived cell therapies. Its core mission is to tackle a range of inflammatory conditions, muscle injuries, and hematological disorders. The company's therapeutic pipeline centers on placental expanded (PLX) cell technology. A key candidate, PLX-PAD, is in advanced clinical development, with ongoing Phase III trials for muscle recovery after hip fracture surgery, Phase II studies for acute respiratory distress syndrome associated with COVID-19, and Phase I/II trials for steroid-refractory Graft-versus-Host Disease. Additionally, Pluri is advancing PLX-R18, a treatment designed to aid in incomplete hematopoietic recovery following hematopoietic cell transplantation and to address acute radiation syndrome. The company rebranded to Pluri Inc. in July 2022, having previously operated as Pluristem Therapeutics Inc.

CEO: Yaacov Yanay
IPO Date: Jun 30, 2003

Market Data

Open: $2.25
High: $2.43
Low: $2.00
Volume: 40.2K
Avg Volume: 10.1K
52W High: $5.96
52W Low: $2.00

Valuation

Market Cap: $18.2M
Enterprise Value: $48.1M
Dividend Yield: 0.00%

Financials

Free Cash Flow: -$19.8M
Revenue: $1.3M
Net Income: -$22.6M
Cash: $5.9M
Debt: $34.1M

Events

EarningsSep 23

EPS est. -0.66